董事
John M. Gill, age 73, is an independent Director at Altimmune, Inc. (NASDAQ: ALT), having served on the board since August 2004 (originally with PharmAthene prior to the 2017 merger).[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill)[[3]](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000046/alt-20250925xdef14a.htm)[[5]](https://altimmune.com/team/john-m-gill/) He serves on the Audit Committee (designated as the financial expert) and the Nominating & Corporate Governance Committee, contributing his deep expertise in financial oversight, biopharma operations, and board governance.[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill)[[3]](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000046/alt-20250925xdef14a.htm)
A Certified Public Accountant (CPA) with a B.A. in Accounting and Economics from Rutgers University, Gill also served in the U.S. Marine Corps.[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill) His career highlights include co-founding TetraLogic Pharmaceuticals (2003–2013, as President, CEO, and Director), serving as President and CEO of PharmAthene, Inc. (2015–2017 until the Altimmune merger), and senior roles at 3-Dimensional Pharmaceuticals (EVP, COO, Director; acquired by Johnson & Johnson in 2003) and SmithKline Beecham/GlaxoSmithKline (R&D executive and finance positions).[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill)[[4]](https://uk.marketscreener.com/insider/MACK-GILL-A04G88/)[[5]](https://altimmune.com/team/john-m-gill/) Recently, on December 23, 2025, Gill purchased 12,500 shares of Altimmune stock at $4.10 per share, owning approximately 12,500 shares with an estimated net worth tied to these holdings of at least $48,250.[[6]](https://www.gurufocus.com/insider/26934/john-gill)[[8]](https://www.marketbeat.com/instant-alerts/john-gill-acquires-12500-shares-of-altimmune-nasdaqalt-stock-2025-12-23/)
查看完整内部人档案 →